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Abstract 
The Fc-fusion mimetic RpR 2 was prepared by disulfide bridging conjugation using a 
PEG in the place of the Fc. RpR 2 displayed higher affinity for VEGF than aflibercept 
caused primarily by a slower dissociation rate, which can prolong a drug at its site of 
action. RpRs have considerable potential for development as stable, organ specific 
therapeutics.   
 
  
 2 
To achieve effective bivalency and high affinity, the two Fabs in an IgG antibody are 
mobile and are linked together as if each Fab (or protein) is bound at the end of linear 
molecule (Figure 1). FpFs 1 are IgG antibody mimetics (Figure 1) designed to have 
enhanced stability and binding properties compared to IgGs. They are prepared from 
PEG-di(mono-sulfone) 3 and two antibody fragments (Fabs).1 Fc-based fusion 
proteins2 (Figure 1) are also capable of exploiting the therapeutic advantages of 
bivalency that are displayed by IgGs. Several Fc-fusion proteins are registered for 
clinical use3 and they will continue to offer considerable clinical potential because of 
Fc recycling, but they can be difficult to produce during early preclinical research and 
to scale for production.4 Fc-fusion proteins are also often prone to aggregation during 
downstream processing5 and have similar stability limitations as IgGs. There are 
therapeutic applications where the Fc is not needed or can cause problems.6 One area 
of interest is the use of antibody based medicines in organ specific applications such 
as the eye. In such cases, Fc recycling does not occur and effector function can be 
deleterious, especially in the treatment of inflammatory conditions. Improved stability 
is important to formulate more concentrated solutions to decrease the frequency of 
dose administration and improved binding properties such as slower dissociation rates 
are important for organ specific targeting. In an effort to further explore the potential of 
antibody-based mimetics that are made using the PEG-di(mono-sulfone) 3 (Scheme 
1A, Figure 1) we describe an Fc-fusion mimetic that we call RpR 2, for receptor binding 
region-PEG-receptor binding region. 
Aflibercept (Eylea) is a Fc-fusion protein that is used to treat age related 
macular degeneration (AMD) by binding to vascular endothelial growth factor (VEGF) 
in the back of the eye. It is administered by intravitreal injection directly into the eye. 
Fc-fusion proteins are related to IgG antibodies in that both have an Fc domain. IgG 
antibodies have two heavy and two light chains. The Fc-domain comprises the C2 and 
C3 regions of the two heavy chains. Interchain disulfides exist in IgG antibodies that 
are between the heavy chains in the hinge region to separate the Fc domain from the 
hinge and Fabs. Aflibercept is a homodimer that comprises 2 monomers of (VEGFR1-
VEGFR2)-(C2-C3), referred to here as VEGFR1-VEGFR2-Fc 5 (Scheme 1B), with 
interchain disulfides expected to be in the peptide sequence between the target 
binding domains (VEGFR1-VEGFR2) and the Fc domain (C2-C3 regions) (Figure 1).7  
Aflibercept is glycosylated with a total molecular weight of 115 kDa, of which 97 kDa 
is due to the protein component. Each mono-sulfone moiety in reagent 3 undergoes 
site-specific conjugation with the two cysteine thiols from an accessible disulfide by a 
sequence of addition-elimination reactions to insert a stable 3-carbon methylene 
bridge between the two thiols of the original disulfide (Scheme S1, ESI).8 The thiol 
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ether bonds in a rebridged disulfide are more stable than the original disulfide bond. 
To make the desired RpR 2 we first had to obtain the VEGFR1-VEGFR2 fragment 4 
by proteolytic digestion of aflibercept to remove the Fc domain (Scheme 1B).  
It was first confirmed that aflibercept migrated to an approximate molecular 
weight of about 115 kDa by SDS PAGE (Figure 2, lane 1). Aflibercept was then treated 
with dithiothreitol (DTT) to reduce the accessible disulfides thought to exist in an hinge 
like region between the binding domain (VEGFR1-VEGFR2) and the Fc domain. A 
broad band appeared at ~55-60 kDa by SDS-PAGE (Figure 2, lane 2). We believe this 
band corresponds to the monomeric VEGFR1-VEGFR2-Fc 5 (Scheme 1B). 
Glycosylation is usually somewhat heterogeneous in therapeutic proteins, so we 
inferred that the broadness of the band at ~55-60 kDa was due to glycosylation 
heterogeneity. DDT was then removed using a PD-10 column and the reduced 
aflibercept solution was incubated with Ellman’s reagent which indicated the presence 
of 4 accessible cysteine thiols in aflibercept (Figure 1S, Table 1S, ESI). This suggested 
that there are 2 cysteines in each VEGFR1-VEGFR2-Fc 5 monomer which can form 
two disulfides in aflibercept analogous to what is found in the hinge region of IgG 
antibodies. Hence it was thought possible that an RpR 2 derived from aflibercept could 
be prepared using the PEG-di(mono-sulfone) 3. If only one cysteine had been present 
in the VEGFR1-VEGFR2-Fc 5 monomer, there are stable, mono-thiol conjugation 
linkers available9 that would have been utilised in a bifunctional reagent analogous to 
PEG-di(mono-sulfone) 3.  
Proteolytic digestion of aflibercept was then examined in an effort to obtain the 
monomeric VEGFR1-VEGFR2 fragment 4 (Scheme 1B). It was necessary that the 
cleavage should in aflibercept should occur to give the monomeric VEGFR1-VEGFR2 
fragment 4 to include the cysteines that form the accessible disulfides in aflibercept. 
Preliminary digestion studies of aflibercept using immobilised papain yielded only 
difficult to characterise small peptide fragments. We had previously used papain to 
digest IgGs to obtain Fabs to make FpFs,1, 10 but recognised that proteolytic digestion 
of different antibody subclasses and motifs can be difficult to control.11   
A second proteolytic enzyme (IdeS enzyme, FabRICATOR®, Genovis) that can 
cleave an IgG at glycine-glycine bonds12 in the hinge reagent to give F(ab)2 was then 
examined. Incubation of aflibercept with IdeS resulted in 3 bands by SDS-PAGE 
(Figure 2, lane 3). New bands appeared at approximately 30 kDa and 60-70 kDa. A 
third band at approximately 95-100 kDa in this gel was thought to be undigested 
aflibercept. The lower molecular weight fragment at 30 kDa, which is thought to be the 
cleaved Fc, and the band for undigested aflibercept were removed by eluting the 
digestion mixture over a column that binds to the Fc domain (CaptureSelect Midispin, 
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Genovis). This provided a purified a non-Fc containing fragment at 60-70 kDa (Figure 
2, lane 4) which was thought to be the VEGFR1-VEGFR2 dimer 6 (Scheme 1B).  
Incubation of VEGFR1-VEGFR2 dimer 6 with DTT caused this fragment to 
disappear to give 2 lower molecular weight fragments (Figure 2, lane 5). These 
fragments are thought to be the desired VEGFR1-VEGFR2 monomer 4 (Scheme 1). 
Two bands are often observed after reduction of Fabs that are obtained by proteolytic 
digestion. This is often thought to be due to miscleavage reactions during proteolysis. 
This may be exacerbated with aflibercept due to structural differences with IgGs and 
aflibercept glycosylation. There are five N-glycosylation sites on each monomeric 
VEGFR1-VEGFR2-Fc fragment 5 which may be partially or completely glycosylated. 
There may also be additional heterogeneity caused by differences in saccharide 
structure in the glycosylated protein.  
To prepare the RpR 2, the VEGFR1-VEGFR2 dimer 6 was first incubated with 
DTT for 30 minutes to give the VEGFR1-VEGFR2 monomer 4 (Scheme 1B). The 
reaction mixture was carefully eluted over a PD-10 column to remove the DTT while 
avoiding disulfide reformation, and then the PEG di(mono-sulfone) reagent 3 (derived 
from a 10 kDa PEG precursor) was added to the solution of the monomeric VEGFR1-
VEGFR2 4. Incubation of the reaction mixture for 3 h (Figure 2S, lane 1, ESI) was then 
followed by purification by size exclusion chromatography (Figure 2S, lanes 2-10, ESI) 
to give the purified RpR 2 which appeared in a band at approximately 70 kDa (Figure 
2, lanes 6 and 7). Two detection dyes were used, first coomassie blue to detect protein 
(lane 6) and then barium iodide to detect the PEG (lane 7) being conjugated to the 
protein. Starting from 0.8 mg (in 1.0 mL) of VEGFR1-VEGFR2 dimer 6, approximately 
0.16 mg (in 0.5 mL) of RpR 2 was obtained (~ 20 % yield). 
At 25˚C the purified RpR 2 displayed a solution size of 10.7 ± 0.5 nm (Pd, 0.7 
± 0.1 nm), which is similar to the starting aflibercept (10.2 ± 0.7 nm; Pd, 0.6 ± 0.1 nm). 
The FpF antibody mimetics 1 were also a similar solution size to the corresponding 
IgG.1 This is in stark contrast to when PEG is conjugated only at one terminus to a 
single protein where the solution size of a PEG-protein conjugate is dominated by the 
random coil nature of PEG.13 When only one terminus of PEG is conjugated to a 
protein, the other PEG terminus has considerable freedom to allow the PEG to 
maintain a large solution structure.  
As macromolecules, both FpF and RpR structures have proteins at each 
terminus of the PEG scaffold which would constrain the motion of the PEG, so these 
antibody mimetics are analogous to A-B-A block copolymers where it is known that 
linear polymers functionalised at both ends can self-associate.14 The dimeric VEGFR1-
VEGFR2 fragment 6 also displayed a solution size of 10.03 ± 0.1 nm (Pd, 0.7 ± 0.1 
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nm) which is similar to both aflibercept and RpR 2. Interestingly, when the VEGFR1-
VEGFR2 fragment 6 was treated with DTT and the cysteine thiols were blocked with 
iodoacetamide, the cysteine thiol-capped monomeric VEGFR1-VEGFR2 fragment 7 
(Scheme 1B) displayed a solution size of 7.2 ± 0.4 nm (Pd, 0.7 ± 0.1 nm). Although 
the dimer 6 is twice the molecular weight of the monomer 7, its solution size is only 
about 40% larger suggesting that there is intramolecular association of the VEGFR1-
VEGFR2 domains within the dimer 6.  
The binding properties of the RpR 2 and aflibercept were then evaluated by 
surface plasmon resonance (Biacore) to determine the affinity (KD), and the rate 
constants of association (ka) and dissociation (kd) (Table 1). Vascular endothelial 
growth factor-165 (VEGF165), which is a ligand for aflibercept, was immobilised at a 
density to minimise or prevent rebinding events (91 RU).1, 15 The dissociation rate (kd) 
for the RpR 2 was slower than what was observed with aflibercept. Interestingly, the 
ka appeared to be slightly faster in RpR 2 compared to aflibercept. This is in contrast 
to what was previously observed for anti-VEGF FpF which had a slower association 
rate than the precursor IgG antibody.1 However it was the decreased kd of RpR 2 that 
appeared to be the dominating factor to cause the improved affinity of RpR 2 compared 
to aflibercept (Table 1). Representative fitting curves for aflibercept and RpR 2 are 
shown in the ESI (Figure S3, ESI). 
Exploiting reduced dissociation rates may be a viable strategy to increase 
efficacy by increasing the residence time and mode of action within specific tissue.16 
Although the reduction in kd for FpF 1 is also slower than the parent IgG,1 there 
appears to be a greater relative reduction in kd for the RpR 2 compared to its parent 
Fc-fusion (i.e. aflibercept). During initial dissociation steps from the ligand of one of the 
two VEGFR1-VEGFR2 domains in the RpR 2, PEG conformational flexibility may be 
more efficient for rebinding than the polypeptide linking the Fc domain to the VEGFR1-
VEGFR2 domain in aflibercept. This suggests there is less flexibility in the bivalent 
binding moieties in the Fc-fusion protein (aflibercept) than there is in an IgG (e.g. 
bevacizumab).   
The VEGF binding of the capped VEGFR1-VEGFR2 monomer 7 (Figure S4, 
ESI) was reduced when compared to the VEGFR1-VEGFR2 dimer 6. This exemplified 
the advantages of the cooperative bivalent binding that is possible with (i) aflibercept, 
(ii) the dimeric VEGFR1-VEGFR2 fragment 6 and (iii) RpR 2 (Table 1). The similar 
binding properties that were observed for both the dimer 6 and aflibercept suggests 
that the placement of the accessible disulfides linking each monomer in aflibercept is 
important for the mobility of the VEGFR1-VEGFR2 binding domains. Inclusion of a 
polypeptide sequence to extend the VEGFR1-VEGFR2 receptor domains away from 
 6 
the aflibercept disulfides to better optimise dissociation rates would be expected to 
make aflibercept less stable. Such an added polypeptide sequence to increase the 
flexibility of the VEGFR1-VEGFR2 receptor domains would invariably lack secondary 
structure in a similar way to the hinge region of IgG antibodies. While the hinge region 
in IgG antibodies provides the flexibility needed for cooperative and bivalent binding of 
both Fabs,17 the IgG hinge region is also vulnerable to degradation and disulfide 
scrambling.18 The stable conjugation imparted by PEG-di(mono-sulfone) 3 and use of 
a PEG scaffold provides enough flexibility of the VEGFR1-VEGFR2 binding moieties 
to potentially maximise both association and dissociation rates that could be important 
in the development of new therapeutics.   
RpR 2 was then evaluated in vitro using a human umbilical vein endothelial cell 
(HUVEC) co-culture (Figure 3). This assay measures the migration and the formation 
of an anastomosing network that is characterised by tubule and junction formation 
during HUVEC proliferation. These processes are characteristic for angiogenesis and 
are often a good in vitro measurement for angiogenesis.19 RpR 2 and aflibercept were 
incubated with VEGF165 at different molar ratios of 3.0, 1.5, 0.5 for 2 hours at 370C 
prior to incubation with HUVECs. VEGF165 and anti-mouse TNF-α IgG were used for 
positive controls. Images were obtained after fixing HUVECs with an anti-CD31 
antibody to differentiate between the endothelial tubular network and non-endothelial 
structures of similar apparent morphology (Figure 3A). These images suggest that both 
aflibercept and the RpR 2 have similar anti-angiogenic properties. Quantification of 
tubule (Figure S5, ESI) and junction formation (Figure 3B) (AngioSys Image Analysis 
Software, TCS Cellworks Ltd.) showed that the formation of these structures were 
similarly inhibited in a concentration dependent manner by both RpR 2 and aflibercept.  
To summarise, a new antibody Fc-fusion mimetic called an RpR was prepared. 
Aflibercept is a clinically used Fc-fusion protein that targets VEGF was used for these 
studies. Proteolytic digestion of aflibercept followed by incubation with DTT provided 
the monomeric VEGFR1-VEGFR2 domain 4 that was then conjugated to the PEG-
di(mono-sulfone) 3 by disulfide bridging conjugation to give the anti-VEGF RpR 2. The 
strategy to proteolytically digest aflibercept provided the means to compare the 
properties of the RpR Fc-fusion mimetic 2 with aflibercept which is an existing, clinically 
used Fc-fusion protein. The solution size of RpR 2 and its in vitro activity are 
comparable to aflibercept. Of most interest is that binding studies show that RpR 2 has 
higher affinity for VEGF compared to aflibercept primarily due to a slower dissociation 
rate. Antibody based mimetics such as RpR 2 have considerable potential for 
development as stable, organ specific therapeutics.   
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Figure Legends 
Figure 1. IgG and Fc fusion proteins and their respective mimetics, FpF 1 and RpR 2.   
Figure 2. SDS-PAGE gels of VEGFR1-VEGFR2 dimer 6 obtained by the proteolytic 
digestion of aflibercept and preparation of RpR 2. Novex Bis-Tris 4-12% gel stained 
with colloidal blue for protein and barium Iodide for PEG (lane 7). M: standard protein 
markers, Lane 1: aflibercept, Lane 2: aflibercept treated with DTT to give VEGF1-
VEGF2-Fc monomer 5, Lane 3: aflibercept-Ides digestion mixture, Lane 4: VEGFR1-
VEGFR2 dimer 6, Lane 5: VEGFR1-VEGFR2 monomer 4, Lanes 6,7: purified RpR 2. 
Figure 3. (A) Representative images that were used for AngioSys analysis to 
quantitate tubule formation using a HUVEC-fibroblast angiogenesis assay. The dark 
structures (tubules) are indicative of angiogenesis and were analysed to determine the 
number of junctions. (B) Number of junctions observed for medium alone, medium + 
VEGF, Anti-mouse TNF-a IgG + VEGF, aflibercept + VEGF and RpR + VEGF. Ratios 
are the amount of test compound to VEGF. VEGF was present at a fixed concentration 
of 10 ng/mL. Data are expressed as the mean of three individual cultures per treatment 
environment. 
 
Scheme Legend 
Scheme 1. (A) Preparation RpR 2 from PEG-di(mono-sulfone) 3 and two equivalents 
of the VEGFR1-VEGFR2 monomer 4. (B) Use of aflibercept to obtain the monomeric 
VEGF1-VEGF2 4 and VEGF1-VEGF2-Fc 5 fragments. Proteolytic digestion of 
aflibercept with the IdeS enzyme results in the cleavage of the Fc to give the VEGFR1-
VEGFR2 dimer 6 that after treatment with DTT gives the VEGFR1-VEGFR2 monomer 
4 which was used to make RpR 2. The VEGFR1-VEGFR2 monomer 4 was also 
incubated iodoacetamide to give the thiol capped VEGFR1-VEGFR2 fragment 7 for 
binding studies.  
 
Table Legend 
Table 1. Binding kinetic constant rate of aflibercept, VEGFR1-VEGFR2 dimer 6 and 
RpR 2 , Affinity, dissociation and association rate constants were studied using CM3 
chip immobilised with 91 RU human VEGF at 250C. The range of concentrations used 
for the conjugates was 0.06 μM to 1.6 μM. Data were collected from 2 independent 
experiments for RpR 2 and 3 independent experiments for aflibercept and VEGFR1-
VEGFR2 dimer 6.  
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